炎性细胞因子在肌萎缩侧索硬化诊断治疗中的研究进展

doi:10.16352/j.issn.1001-6325.2022.06.012

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (6): 964-968.doi: 10.16352/j.issn.1001-6325.2022.06.012

炎性细胞因子在肌萎缩侧索硬化诊断治疗中的研究进展

李晓光^1*, 杨璐¹, 刘旭东², 贾鑫淼², 程燕飞^1,3, 崔丽英^1*

中国医学科学院北京协和医学院北京协和医院 1.神经内科; 2.医学科学研究中心,北京 100730;
3.山西医科大学第七临床医学院临汾市人民医院神经内科, 山东临汾 041000

收稿日期:2022-02-22 修回日期:2022-04-22 出版日期:2022-06-05 发布日期:2022-06-02
通讯作者: * pumchxgli@sina.com;pumchcuily@sina.com
基金资助:
国家自然科学基金(81750002);吴阶平医学基金会临床科研专项资助基金(320675017092);中国医学科学院医学与健康科技创新工程(2021I2MC&TA003);北京亦城合作发展基金会科研项目(YJXJJZ2021001406)

Research progress of inflammatory cytokines in the diagnosis and treatment of amyotrophic lateral sclerosis

LI Xiao-guang^1*, YANG Lu¹, LIU Xu-dong², JIA Xin-miao², CHENG Yan-fei^1,3, CUI Li-ying^1*

1. Department of Neurology; 2. Centre for Medical Science Research,Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730;
3. Department of Neurology, Linfen People's Hospital, the Seventh Clinical Medical College of Shanxi Medical University, Linfen 041000, China

Received:2022-02-22 Revised:2022-04-22 Online:2022-06-05 Published:2022-06-02
Contact: * pumchxgli@sina.com;pumchcuily@sina.com

摘要/Abstract

摘要： 肌萎缩侧索硬化(ALS)是一种多个基因参与的复杂疾病,涉及多种机制。神经炎性反应是其中机制之一,有许多炎性细胞因子参与,其有可能作为生物标志物及治疗靶点应用于临床。突变基因编码的许多蛋白质可损害免疫系统功能,导致免疫功能失调,驱动中枢神经系统和外周免疫系统的炎性反应。炎性细胞因子种类较多,水平变化较大,受疾病阶段、类型及共病影响,目前在ALS中的结果尚不一致,无单一炎性细胞因子可做为特异标志物。炎性细胞因子做为治疗监测标志物及靶点有一定前景。

关键词: 肌萎缩侧索硬化, 基因变异, 炎性细胞因子

Abstract: Amyotrophic lateral sclerosis (ALS) is a multifactor, multiple genes disease which involving a variety of mechanisms. Neuroinflammatory response is one of the mechanisms. Many inflammatory cytokines are involved. It may be used in clinic as biomarkers and therapeutic targets. Many proteins encoded by mutant genes can damage the function of immune system, lead to immune dysfunction and drive the inflammatory response of central nervous system and peripheral immune system. There are many kinds of inflammatory cytokines with great diversification in their levels which influenced by the stage, type and comorbidity of the disease, the results are not consistent at present, and there is no single inflammatory cytokine identified as a specific marker. Inflammatory cytokines have a certain prospect as therapeutic monitoring markers and targets.

Key words: amyotrophic lateral sclerosis, gene variant, inflammatory cytokines

中图分类号:

R746.4

李晓光, 杨璐, 刘旭东, 贾鑫淼, 程燕飞, 崔丽英. 炎性细胞因子在肌萎缩侧索硬化诊断治疗中的研究进展[J]. 基础医学与临床, 2022, 42(6): 964-968.

LI Xiao-guang, YANG Lu, LIU Xu-dong, JIA Xin-miao, CHENG Yan-fei, CUI Li-ying. Research progress of inflammatory cytokines in the diagnosis and treatment of amyotrophic lateral sclerosis[J]. Basic & Clinical Medicine, 2022, 42(6): 964-968.

参考文献

[1] Beers DR, Appel SH. Immune dysregulation in amyotro-phic lateral sclerosis: mechanisms and emerging therapies[J]. Lancet Neurol,2019,18:211-220.
[2] Brodovitch A, Boucraut J, Delmont E, et al. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS[J]. Sci Rep, 2021, 11:703. doi: 10.1038/s41598-020-80370-6.
[3] Rolfes L, Schulte-Mecklenbeck A, Schreiber S, et al. Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation[J]. Brain Commun, 2021, 3:fcab157. doi: 10.1093/braincomms/fcab157.
[4] Lu CH, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis[J]. Neurol Neuroimmunol Neuroinflamm, 2016,3:e244. doi: 10.1212/NXI.0000000000000244.
[5] Du Y, Zhao W, Thonhoff JR, et al. Increased activation ability of monocytes from ALS patients[J]. Exp Neurol, 2020,328:113259. doi: 10.1016/j.expneurol.2020.113259.
[6] Kurashige T, Kuramochi M, Ohsawa R, et al. Optineurin defects cause TDP43-pathology with autophagic vacuolar formation[J]. Neurobiol Dis, 2021,148:105215. doi: 10.1016/j.nbd.2020.105215.
[7] Harding O, Evans CS, Ye J, et al. ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy[J]. Proc Natl Acad Sci U S A, 2021, 118:e2025053118. doi: 10.1073/pnas.2025053118.
[8] Ye J, Cheung J, Gerbino V, et al. Effects of ALS-associated TANK binding kinase 1 mutations on protein-protein interactions and kinase activity[J]. Proc Natl Acad Sci U S A, 2019,116:24517-24526.
[9] Yilmaz R, Müller K, Brenner D, et al. SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden[J]. Neurobiol Aging, 2020,87:139. doi: 10.1016/j.neurobiolaging.2019.10.018.
[10] Ando T, Nakamura R, Kuru S, et al. The wide-ranging clinical and genetic features in Japanese families with valosin-containing protein proteinopathy[J]. Neurobiol Aging, 2021,100:120.e1-120.e6.
[11] Olesen MN, Wuolikainen A, Nilsson AC, et al. Inflammatory profiles relate to survival in subtypes of amyotro-phic lateral sclerosis[J]. Neurol Neuroimmunol Neuroinflamm, 2020,7:e697. doi: 10.1212/NXI.0000000000000697.
[12] Polverino A, Rucco R, Stillitano I, et al. In amyotrophic lateral sclerosis blood cytokines are altered, but do not correlate with changes in brain topology[J]. Brain Connect, 2020,10:411-421.
[13] Prado LGR, Rocha NP, de Souza LC, et al. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis[J]. J Neurol Sci, 2018, 394:69-74.
[14] Martinez-Merino L, Iridoy M, Galbete A, et al. Evalua-tion of chitotriosidase and CC-chemokine ligand 18 as biomarkers of microglia activation in amyotrophic lateral sclerosis[J]. Neurodegener Dis, 2018,18:208-215.
[15] Pronto-Laborinho A, Pinto S, Gromicho M, et al. Interleukin-6 and amyotrophic lateral sclerosis[J]. J Neurol Sci,2019, 398:50-53.
[16] Tortelli R, Zecca C, Piccininni M, et al. plasma inflammatory cytokines are elevated in ALS[J]. Front Neurol, 2020, 552295. doi: 10.3389/fneur.2020.552295.
[17] Huang F, Zhu Y, Hsiao-Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis[J]. Ann Clin Transl Neurol, 2020, 7:1103-1116.
[18] Wosiski-Kuhn M, Robinson M, Strupe J, et al. IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 6:e631. doi: 10.1212/NXI.0000000000000631.
[19] Wosiski-Kuhn M, Caress JB, Cartwright MS, et al. Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2021, 22:248-259.
[20] Yuan S, Roos PM, Larsson SC. Interleukin-1 receptor antagonist, interleukin-2 receptor alpha subunit and amyotrophic lateral sclerosis[J]. Eur J Neurol, 2020, 27:1913-1917.
[21] Milligan C, Atassi N, Babu S, et al. Tocilizumab is safe and tolerable and reduces C-reactive protein concentra-tions in the plasma and cerebrospinal fluid of ALS patients[J]. Muscle Nerve, 2021, 64:309-320.
[22] Fournier CN, Schoenfeld D, Berry JD, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2018, 19:242-249.
[23] Camu W, Mickunas M, Veyrune JL, et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial[J]. EBioMedicine, 2020, 59:102844. doi: 10.1016/j.ebiom.2020.102844.

炎性细胞因子在肌萎缩侧索硬化诊断治疗中的研究进展

Research progress of inflammatory cytokines in the diagnosis and treatment of amyotrophic lateral sclerosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	李晓光, 杨璐, 刘旭东, 贾鑫淼, 杨欣壮, 崔丽英. 基因治疗肌萎缩侧索硬化机制的研究进展[J]. 基础医学与临床, 2023, 43(4): 674-679.
[2]	刘立洋, 柳青, 刘雅萍, 张学. 线粒体功能障碍在肌萎缩侧索硬化发病中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 332-335.
[3]	梁文林, 李军, 金光明, 闫晋升, 姚远. 黄芪甲苷对系膜增生性肾小球肾炎小鼠肾功能及血清IL-1β和IL-17的影响[J]. 基础医学与临床, 2020, 40(12): 1666-1670.
[4]	丁康, 张烽萍, 王淑坤, 刘美逸, 蒋欣, 陈燕春, 周风华. BDNF在ALS转基因小鼠活化星形胶质细胞中表达升高[J]. 基础医学与临床, 2020, 40(11): 1474-1478.
[5]	杨颂杨云云焦晓璐朱苗苗李娟秦彦文. 血管生成素样蛋白8基因罕见突变与严重高三酰甘油血症[J]. 基础医学与临床, 2018, 38(5): 622-625.